Sartorius Stedim Biotech expands manufacturing and R&D capacities for innovative bioprocess solutions in France
17.06.25 16:00 Uhr
Werbung
Werte in diesem Artikel
|
Sartorius Stedim Biotech SA
/ Key word(s): Expansion
Werbung Werbung Aubagne, France | June 17, 2025
Sartorius Stedim Biotech expands manufacturing and R&D capacities for innovative bioprocess solutions in France
Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today celebrates the completion of a multi-year capacity expansion project at its headquarters in Aubagne, France. Launched in 2021, the investments in several new facilities underscore the company’s dedication to providing customers with innovative fluid management technologies such as single-use bags, used for cell culture, storage and shipping of fluids in biopharmaceutical manufacturing.
“By investing in innovation, automation, and sustainability, we are strengthening our ability to meet the evolving needs of our customers while ensuring our competitive positioning and preparing for future growth. This emphasizes our commitment to simplify and accelerate progress in bioprocessing with advanced technologies, enabling new and better therapies to be manufactured faster, more efficiently and more sustainably,” said René Fáber, CEO of Sartorius Stedim Biotech. To meet the growing demand for single-use bioprocessing solutions, Sartorius Stedim Biotech almost doubled cleanroom space to around 9,000 square meters. Automated and digitized production lines for 2D and 3D single-use bags increase productivity and reliability. Certified with ISCC Plus1, the site uses renewable raw materials to produce plastic components, significantly reducing the share of fossil-based materials in products. The company also adopted ISO 14001, a standard for environmental management systems, to improve the environmental performance and reduce the ecological footprint of its operations. An automated logistics facility accelerates raw material handling for single-use bag manufacturing. The new 12,000-square-meter high-bay warehouse is optimized for efficient processing of pallets. Autonomous forklifts and mobile robots streamline operations utilizing a Goods-To-Person approach, enabling operators to focus on specialized work. The facility will be fully operational by fall 2025. The expanded site also includes a new 1,900-square-meter cross-functional lab space, designed to extend collaboration between internal teams and external partners. The facility houses product development labs for fluid management and cell culture technologies, as well as application labs for customer demos and training. It opened its doors to customers in early 2024. A modern office building at the center of the campus, including a showroom and a conference center, as well as amenities such as a restaurant and a gym, complement the new facilities. The total area of the premises has quadrupled to around 90,000 square meters since 2020. Designed to meet high environmental standards and minimize the ecological footprint of the facility, the buildings earned HQE® Excellent and BiodiverCity® certifications for sustainable construction and biodiversity measures. Since 2021, Sartorius Stedim Biotech has invested significantly in its French operations, including Lourdes, Cergy, Pompey, and Strasbourg. Today, around 1,400 employees work at seven sites in France-thereof more than 1,100 in Aubagne. Over the past ten years, the number of employees in the country has approximately doubled. 1 International Sustainability and Carbon Certification PLUS (ISCC PLUS)
Further information Find images of Sartorius Stedim Biotech Aubagne here A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, more safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. Currently, more than 9,900 employees are working for customers around the globe. Visit our Newsroom or follow us on LinkedIn. Contacts Petra Kirchhoff Head of Corporate Communications & IR +49 551 308 1686 petra.kirchhoff@sartorius.com Attachment File: Sartorius Stedim Biotech expands manufacturing and R&D capacities for innovative bioprocess solutions in France | Media Release
Dissemination of a Financial Wire News, transmitted by EQS Group. |
| Language: | English |
| Issuer: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | sartorius.presse@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | FR0013154002 |
| EQS News ID: | 2155962 |
| End of Announcement - EQS News Service | |
|
|
Werbung
Werbung
2155962 17-Jun-2025 CET/CEST
Ausgewählte Hebelprodukte auf Sartorius Stedim Biotech
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sartorius Stedim Biotech
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Nachrichten zu Sartorius Stedim Biotech
Werbung
Analysen zu Sartorius Stedim Biotech
| Datum | Rating | Analyst | |
|---|---|---|---|
| 06.06.2025 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 25.04.2025 | Sartorius Stedim Biotech Overweight | JP Morgan Chase & Co. | |
| 23.04.2025 | Sartorius Stedim Biotech Buy | Jefferies & Company Inc. | |
| 16.04.2025 | Sartorius Stedim Biotech Overweight | JP Morgan Chase & Co. | |
| 16.04.2025 | Sartorius Stedim Biotech Market-Perform | Bernstein Research |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 25.04.2025 | Sartorius Stedim Biotech Overweight | JP Morgan Chase & Co. | |
| 23.04.2025 | Sartorius Stedim Biotech Buy | Jefferies & Company Inc. | |
| 16.04.2025 | Sartorius Stedim Biotech Overweight | JP Morgan Chase & Co. | |
| 16.04.2025 | Sartorius Stedim Biotech Outperform | RBC Capital Markets | |
| 21.02.2025 | Sartorius Stedim Biotech Outperform | RBC Capital Markets |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 06.06.2025 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 16.04.2025 | Sartorius Stedim Biotech Market-Perform | Bernstein Research | |
| 29.01.2025 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 24.01.2025 | Sartorius Stedim Biotech Neutral | UBS AG | |
| 22.10.2024 | Sartorius Stedim Biotech Neutral | UBS AG |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 29.07.2024 | Sartorius Stedim Biotech Underperform | Bernstein Research |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sartorius Stedim Biotech nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"